Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?

References

• Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333–1341.
   PubMed Web of Science ®Google Scholar
• Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391(10123):850–859.
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological, D. and P.A.S.S.G. Stroke rt. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587.
   PubMedGoogle Scholar
• Hacke W, Kaste M, Bluhmki E, et al., Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 359(13): 1317–1329. 2008.
   PubMed Web of Science ®Google Scholar
• Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific Statement for healthcare professionals from the American heart association/American stroke association. Stroke. 2017;48(12):e343–e361.
   PubMed Web of Science ®Google Scholar
• Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs. 2013;13(1):57–69.
   PubMed Web of Science ®Google Scholar
• Henderson SJ, Weitz JI, Kim PY. Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke. J Thromb Haemost. 2018;16(10):1932–1940.
   PubMedGoogle Scholar
• Berkhemer OA, Fransen PSS, Beumer DW. A Randomized Trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.
   PubMed Web of Science ®Google Scholar
• Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–1018.
   PubMed Web of Science ®Google Scholar
• Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–1030.
   PubMed Web of Science ®Google Scholar
• Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–2306.
   PubMed Web of Science ®Google Scholar
• Saver JL, Goyal M, Bonafe A, et al., Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 372(24): 2285–2295. 2015.
   PubMed Web of Science ®Google Scholar
• Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016;316(12):1279–1288.
   PubMed Web of Science ®Google Scholar
• Kaesmacher J, Maamari B, Meinel TR, et al. Effect of pre- and in-hospital delay on reperfusion in acute ischemic stroke mechanical thrombectomy. Stroke. 2020;51(10):2934–2942.
   PubMedGoogle Scholar
• Schulz VC, de Magalhaes PSC, Carneiro CC, et al. Improved outcomes after reperfusion therapies for ischemic stroke: a “Real-world” study in a developing country. Curr Neurovasc Res. 2020;17(4):361–375.
   PubMedGoogle Scholar
• Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.
   PubMed Web of Science ®Google Scholar
• Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–718.
   PubMed Web of Science ®Google Scholar
• Thomalla G, Simonsen CZ, Boutitie F, et al., MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 379(7): 611–622. 2018.
   PubMed Web of Science ®Google Scholar
• Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795–1803.
   PubMed Web of Science ®Google Scholar
• Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I–LXII.
   PubMed Web of Science ®Google Scholar
• Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO) – European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischaemic stroke endorsed by stroke alliance for Europe (SAFE). Eur Stroke J. 2019;4(1):6–12.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2019;50(12):e344–e418.
   PubMed Web of Science ®Google Scholar
• Dawson J, Merwick Á, Webb A, et al. European stroke organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J. 2021;6(2):CLXXXVII–CXCI.
   PubMedGoogle Scholar
• Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association/American stroke association. Stroke. 2021;52(7):e364–e467.
   PubMed Web of Science ®Google Scholar
• Brown DL, Levine DA, Albright K, et al. Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2021;52(7):e468–e479.
   PubMedGoogle Scholar
• Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–337.
   PubMed Web of Science ®Google Scholar
• Investigators SPS, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–825.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.
   PubMed Web of Science ®Google Scholar
• Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215–225.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–19.
   PubMed Web of Science ®Google Scholar
• De Schryver EL, Algra A, Kappelle LJ, et al. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev. 2012;2012(9):CD001342.
   Google Scholar
• Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–1451.
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, et al. European stroke prevention study. 2. dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.
   PubMed Web of Science ®Google Scholar
• Group ES, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665–1673.
   PubMedGoogle Scholar
• Kwok CS, Shoamanesh A, Copley HC, et al. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke. 2015;46(4):1014–1023.
   PubMedGoogle Scholar
• Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–1251.
   PubMed Web of Science ®Google Scholar
• Naqvi IA, Kamal AK, Rehman H. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2020;8(9):CD009716.
   PubMedGoogle Scholar
• Johnston SC, Amarenco P, Denison H, et al., Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.Evans. N Engl J Med. 383(3): 207–217. 2020.
   PubMed Web of Science ®Google Scholar
• Cote R, Zhang Y, Hart RG, et al. ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology. 2014;82(5):382–389.
   PubMedGoogle Scholar
• Kim J-T, Park M-S, Choi K-H, et al. Different antiplatelet strategies in patients with new ischemic stroke while taking aspirin. Stroke. 2016;47(1):128–134.
   PubMedGoogle Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–1214.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al., 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. 74(1): 104–132. 2019.
   PubMed Web of Science ®Google Scholar
• Caturano A, Galiero R, Pafundi PC. Atrial fibrillation and stroke. a review on the use of vitamin K antagonists and novel oral anticoagulants. Medicina (Kaunas). 2019;55(10). https://doi.org/10.3390/medicina55100617
   Google Scholar
• Caprio FZ, Sorond FA. Cerebrovascular disease: primary and secondary stroke prevention. Med Clin North Am. 2019;103(2):295–308.
   PubMed Web of Science ®Google Scholar
• O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–775.
   PubMed Web of Science ®Google Scholar
• Patel SA, Winkel M, Ali MK, et al. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163(4):245–253.
   PubMed Web of Science ®Google Scholar
• Diener H-C, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage. J Am Coll Cardiol. 2020;75(15):1804–1818.
   PubMed Web of Science ®Google Scholar
• Popa-Wagner A, Petcu EB, Capitanescu B, et al. Ageing as a risk factor for cerebral ischemia: underlying mechanisms and therapy in animal models and in the clinic. Mech Ageing Dev. 2020;190:111312.
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020;106(1):10–17.
   PubMed Web of Science ®Google Scholar
• Chen Z, Seiffert D, Hawes B. Inhibition of factor XI activity as a promising antithrombotic strategy. Drug Discov Today. 2014;19(9):1435–1439.
   PubMedGoogle Scholar
• Srivastava P, Gailani D. The rebirth of the contact pathway: a new therapeutic target. Curr Opin Hematol. 2020;27(5):311–319.
   PubMedGoogle Scholar
• Tillman BF, Gruber A, McCarty OJT, et al. Plasma contact factors as therapeutic targets. Blood Rev. 2018;32(6):433–448.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116(22):4684–4692.
   PubMed Web of Science ®Google Scholar
• Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102–2107.
   PubMed Web of Science ®Google Scholar
• Koch AW, Schiering N, Melkko S, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019;133(13):1507–1516.
   PubMed Web of Science ®Google Scholar
• Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy?: an analysis of patient eligibility. Neurology. 2001;56(8):1015–1020.
   PubMed Web of Science ®Google Scholar
• Hacke W, Lyden P, Emberson J, et al. Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: individual-patient-data meta-analysis of randomized trials. Int J Stroke. 2018;13(2):175–189.
   PubMedGoogle Scholar
• Coutts SB, Berge E, Campbell BC, et al. Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials. Int J Stroke. 2018;13(9):885–892.
   PubMed Web of Science ®Google Scholar
• Hurd MD, Goel I, Sakai Y, et al. Current status of ischemic stroke treatment: from thrombolysis to potential regenerative medicine. Regen Ther. 2021;18:408–417.
   PubMedGoogle Scholar
• Shibata K, Hashimoto T, Miyazaki T, et al. Thrombolytic therapy for acute ischemic stroke: past and future. Curr Pharm Des. 2019;25(3):242–250.
   PubMed Web of Science ®Google Scholar
• Binbrek AS, Rao NS, Neimane D, et al. Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. Am J Cardiol. 2004;93(12):1465–1468.
   PubMedGoogle Scholar
• Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995;92(10):3032–3040.
   PubMed Web of Science ®Google Scholar
• Liaw N, Liebeskind D. Emerging therapies in acute ischemic stroke. F1000Res. 2020;9:546.
   Google Scholar
• Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781–788.
   PubMed Web of Science ®Google Scholar
• Campbell BCV, Mitchell PJ, Churilov L, et al. tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573–1582.
   PubMed Web of Science ®Google Scholar
• Xu N, Chen Z, Zhao C, et al. Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials. Drug Des Devel Ther. 2018;12:2071–2084.
   PubMed Web of Science ®Google Scholar
• Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol. 2012;165(1):75–89.
   PubMed Web of Science ®Google Scholar
• Mori E, Minematsu K, Nakagawara J, et al. Safety and tolerability of desmoteplase within 3 to 9 hours after symptoms onset in Japanese patients with ischemic stroke. Stroke. 2015;46(9):2549–2554.
   PubMedGoogle Scholar
• Albers GW, von Kummer R, Truelsen T, et al. Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14(6):575–584.
   PubMed Web of Science ®Google Scholar
• Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8(2):141–150.
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation Of Desmoteplase For Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37(5):1227–1231.
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36(1):66–73.
   PubMed Web of Science ®Google Scholar
• von Kummer R, Mori E, Truelsen T, et al. Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 trial (efficacy and safety study of desmoteplase to treat acute ischemic stroke). Stroke. 2016;47(12):2880–2887.
   PubMed Web of Science ®Google Scholar
• Huang Y, Ohta Y, Shang J, et al. Reduction of ischemia reperfusion-related brain hemorrhage by stachybotrys microspora triprenyl phenol-7 in mice with antioxidant effects. J Stroke Cerebrovasc Dis. 2018;27(12):3521–3528.
   PubMedGoogle Scholar
• Gusev EI, Martynov MY, Nikonov AA, et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721–728.
   PubMedGoogle Scholar
• Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. the PROACT II study: a randomized controlled trial. prolyse in acute cerebral thromboembolism. JAMA. 1999;282(21):2003–2011.
   PubMed Web of Science ®Google Scholar
• Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59(6):862–867.
   PubMed Web of Science ®Google Scholar
• Rubiera M, Alvarez-Sabin J, Ribo M, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005;36(7):1452–1456.
   PubMed Web of Science ®Google Scholar
• Barreto AD, Alexandrov AV. Adjunctive and alternative approaches to current reperfusion therapy. Stroke. 2012;43(2):591–598.
   PubMed Web of Science ®Google Scholar
• Harsany M, Tsivgoulis G, Alexandrov AV. Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications. Expert Rev Neurother. 2014;14(8):879–892.
   PubMed Web of Science ®Google Scholar
• Mikael Mazighi YP, Comenducci A, Lapergue B, et al. Abstract 14738: actimis trial: safety and efficacy evaluation of ACT017, a novel antiplatelet agent on top of acute ischemic stroke standard of care. Circulation. 2019;140(Suppl_1).
   Google Scholar
• Jandrot-Perrus M, Busfield S, Lagrue AH, et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood. 2000;96(5):1798–1807.
   PubMed Web of Science ®Google Scholar
• Zahid M, Mangin P, Loyau S, et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost. 2012;10(12):2418–2427.
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018;15(3):181–191.
   PubMed Web of Science ®Google Scholar
• Renaud L, Lebozec K, Voors-Pette C, et al. Population pharmacokinetic/pharmacodynamic modeling of glenzocimab (ACT017) a glycoprotein VI inhibitor of collagen-induced platelet aggregation. J Clin Pharmacol. 2020;60(9):1198–1208.
   PubMed Web of Science ®Google Scholar
• Pancioli AM, Broderick J, Brott T, et al. The C ombined approach to L ysis utilizing E ptifibatide a nd r t-PA in acute ischemic stroke. Stroke. 2008;39(12):3268–3276.
   PubMedGoogle Scholar
• Adeoye O, Sucharew H, Khoury J, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial. Stroke. 2015;46(9):2529–2533.
   PubMedGoogle Scholar
• Adeoye O, Sucharew H, Khoury J, et al. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. Stroke. 2015;46(2):461–464.
   PubMedGoogle Scholar
• Pancioli AM, Adeoye O, Schmit PA, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke. 2013;44(9):2381–2387.
   PubMedGoogle Scholar
• Li W, Lin L, Zhang M, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke. 2016;47(10):2649–2651.
   PubMedGoogle Scholar
• Pinzon RT, Tjandrawinata RR, Wijaya VO, et al. Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: a Randomized Controlled Trial. Stroke Res Treat. 2021;2021:5541616.
   PubMedGoogle Scholar
• Barreto AD, Ford GA, Shen L, et al. Randomized, multicenter trial of ARTSS-2 (argatroban with recombinant tissue plasminogen activator for acute stroke). Stroke. 2017;48(6):1608–1616.
   PubMedGoogle Scholar
• Hou X, Jin C, Pan C, et al. Effects of argatroban therapy for stroke patients: a meta-analysis. J Clin Neurosci. 2021;90:225–232.
   PubMed Web of Science ®Google Scholar
• Heiss WD. Malignant MCA infarction: pathophysiology and imaging for early diagnosis and management decisions. Cerebrovasc Dis. 2016;41(1–2):1–7.
   PubMed Web of Science ®Google Scholar
• Beez T, Munoz-Bendix C, Steiger HJ, et al. decompressive craniectomy for acute ischemic stroke. Crit Care. 2019;23(1):209.
   PubMedGoogle Scholar
• van der Worp HB, Hofmeijer J, Juttler E, et al. European Stroke Organisation (ESO) guidelines on the management of space-occupying brain infarction. Eur Stroke J. 2021;6(2):XC–CX.
   PubMedGoogle Scholar
• Kimberly WT, Battey TW, Pham L, et al. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014;20(2):193–201.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39(8):2249–2256.
   PubMed Web of Science ®Google Scholar
• England TJ, Bath PM, Sare GM, et al. Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the tinzaparin in acute ischaemic stroke trial. Stroke. 2010;41(12):2834–2839.
   PubMedGoogle Scholar
• Wang X, Ouyang M, Yang J, et al. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2021;10(10):CD000024.
   PubMedGoogle Scholar
• Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European stroke organisation guideline. Eur Stroke J. 2019;4(3):198–223.
   PubMedGoogle Scholar
• Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke. 2015;46(8):2175–2182.
   PubMed Web of Science ®Google Scholar
• McGrath ER, Eikelboom JW, Kapral MK, et al. Novel oral anticoagulants: a focused review for stroke physicians. Int J Stroke. 2014;9(1):71–78.
   PubMedGoogle Scholar
• Johnson ES, Lanes SF, Wentworth CE, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med. 1999;159(11):1248–1253. 3rd.
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum, JW, Kelder, JC et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754–762.
   PubMed Web of Science ®Google Scholar
• John S, Katzan I. Recurrent stroke while on antiplatelet therapy. Neurol Clin. 2015;33(2):475–489.
   PubMedGoogle Scholar
• Yan AR, Naunton M, Peterson GM, et al. Effectiveness of platelet function analysis-guided aspirin and/or clopidogrel therapy in preventing secondary stroke: a systematic review and meta-analysis. J Clin Med. 2020;9(12):3907.
   Google Scholar
• FADOI CS 2022 jan 13; Available from: https://centrostudifadoi.org/astro-fadoi-01-2018/.
   Google Scholar
• Bicciato G, Arnold M, Gebhardt A, et al. Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion. Curr Opin Neurol. 2022;35(1):45–54.
   PubMedGoogle Scholar
• Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study. J Am Heart Assoc. 2017;6(12). https://doi.org/10.1161/JAHA.117.007034.
   Google Scholar
• Saliba W, Schliamser JE, Lavi I, et al. Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: a propensity score-matched analysis. Heart Rhythm. 2017;14(5):635–642.
   PubMedGoogle Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330.
   PubMed Web of Science ®Google Scholar
• Perera KS, Ng KKH, Nayar S, et al., Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial. JAMA Neurol. 77(1): 43–48. 2020.
   PubMedGoogle Scholar
• Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–2201.
   PubMed Web of Science ®Google Scholar
• Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–1917.
   PubMed Web of Science ®Google Scholar
• Ntaios G. Embolic stroke of undetermined source: JACC review topic of the week. J Am Coll Cardiol. 2020;75(3):333–340.
   PubMed Web of Science ®Google Scholar
• Yaghi S, Boehme AK, Hazan R, et al. Atrial cardiopathy and cryptogenic stroke: a cross-sectional pilot study. J Stroke Cerebrovasc Dis. 2016;25(1):110–114.
   PubMed Web of Science ®Google Scholar
• Yaghi S, Kamel H, Elkind MSV. Atrial cardiopathy: a mechanism of cryptogenic stroke. Expert Rev Cardiovasc Ther. 2017;15(8):591–599.
   PubMed Web of Science ®Google Scholar
• Kamel H, Longstreth WT, D.L. Tirschwell J, et al. The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14(2):207–214.
   PubMed Web of Science ®Google Scholar
• Gupta R, Lin M, Mehta A, et al. Protease-activated receptor antagonist for reducing cardiovascular events - a review on vorapaxar. Curr Probl Cardiol 2021 101035 https://doi.org/10.1016/j.cpcardiol.2021.101035
   Google Scholar
• Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Drugs. 2010;70(14):1771–1783.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012;380(9850):1317–1324.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20–33.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Kim MH, Fortmann SD, et al. Vorapaxar for secondary stroke prevention: perspectives and obstacles. Expert Rev Neurother. 2015;15(12):1377–1382.
   PubMed Web of Science ®Google Scholar
• Demel SL, Stanton R, Aziz YN, et al. Reflection on the past, present, and future of thrombolytic therapy for acute ischemic stroke. Neurology. 2021;97(20 Suppl 2):S170–S177.
   PubMedGoogle Scholar